Where is Ascendis Pharma located?
Ascendis Pharma operates through a strategically distributed model with two primary operational hubs. Its legal and global corporate headquarters is situated in Hellerup, Denmark, serving as the central base for its research, development, and administrative management. Furthermore, the company maintains a massive and critical operational presence in Palo Alto, California, which serves as the primary U.S. headquarters for its clinical development, regulatory affairs, and commercialization teams. This structure allows the company to integrate world-class European pharmaceutical research with the dynamic commercial and clinical resources found in the Silicon Valley biotech hub. By bridging these two major international life sciences centers, Ascendis manages a seamless global strategy for its proprietary TransCon drug technology and clinical trials, effectively serving its diverse patient populations in Europe, the United States, and beyond.
Related FAQs
Employee reviews and corporate workplace evaluations for Ascendis Pharma consistently highlight a collaborative scientific environment, competitive compensation packages, and robust professional growth opportunities within the biotechnology sector.
Ashtead Group (operating primarily through its Sunbelt Rentals subsidiary) commands a massive equipment rental fleet valued at over $15 billion across its operations in the United States, alongside substantial fleet allocations in Canada and the Unit...
Ascendis Pharma is a biopharmaceutical company utilizing its proprietary TransCon technology platform to develop a robust pipeline of long-acting prodrug therapies that address unmet medical needs in rare endocrine diseases and oncology.
Ascendis Pharma maintains deep corporate roots and operational headquarters in Copenhagen, Denmark, establishing its primary European identity while operating globally.
Ascendis Pharma operates as a fully public corporate entity, listed and traded on major global stock exchanges including The Nasdaq Global Select Market under its primary ticker designation.
Equity research analysts tracking Ascendis Pharma (ticker ASND) frequently assign consensus ratings leaning toward a buy or strong buy, driven by the successful commercial expansion of its innovative endocrinology therapeutics and growing global reve...
Ascendis Pharma A/S, traded under the ticker symbol ASND, belongs to the healthcare sector and operates specifically within the biotechnology and biopharmaceutical industry.
Ascendis Pharma A/S (ASND) maintains a strong consensus Buy rating among biopharmaceutical analysts, with average 12-month price targets clustering around $309.18 per share.
ASSA ABLOY AB, the global leader in access solutions and physical security products, employs approximately 55,000 to 64,000 personnel worldwide across its various specialized divisions and operating subsidiaries.
Ascendis Health underwent extensive corporate restructuring, debt-reduction initiatives, and strategic asset divestments to address historical financial leverage and streamline operations.
Ascendis Pharma has successfully transitioned into a profitable commercial-stage enterprise, generating robust product revenues from its flagship commercial therapies alongside positive operating profits and growing cash flows.
Ascendis Pharma A/S is a global biopharmaceutical company headquartered in Hellerup, Denmark, which is a northern suburb of Copenhagen.
Ascendis Pharma demonstrates exceptional growth prospects driven by the successful commercial scaling of its proprietary TransCon technology platform and flagship commercial products like YORVIPATH.
Ascendis Pharma develops and manufactures a specialized portfolio of therapeutic products utilizing its proprietary TransCon technology platform, which is designed to create long-acting prodrugs that release active parent medications steadily over ti...
ASE Technology Holding Co., Ltd. commands a market capitalization of approximately $83.20 billion to $86.68 billion USD, positioning it as a dominant global leader in semiconductor packaging and testing services.
Ascendis Pharma is widely recognized as an innovative, highly respected global biopharmaceutical enterprise dedicated to developing advanced therapies using its proprietary TransCon technology platform.
Bausch + Lomb Corporation (NYSE: BLCO) stock has experienced moderate downward volatility and relative pressure over past annual cycles, trading down roughly 21 percent over a trailing one-year period.
Ascendis Pharma A/S, trading under the ticker ASND on the Nasdaq stock exchange, operates as a biopharmaceutical enterprise utilizing its proprietary TransCon technology platform to develop best-in-class therapeutics for unmet medical needs, includin...
Ascendis Pharma utilizes its proprietary TransCon technology platform to develop innovative long-acting prodrug therapies designed to address unmet medical needs in endocrinology and rare diseases.
Corporate entities operating under the name Ascendis—specifically major biopharmaceutical operations—have achieved profitability milestones driven by strong commercial product sales, growing international market penetration, and disciplined cost cont...
Ascendis Pharma is a commercial-stage biopharmaceutical company globally known for applying its innovative proprietary TransCon technology platform to develop best-in-class therapeutics that address significant unmet medical needs in endocrinology an...
Ascendis Pharma is a biopharmaceutical enterprise dedicated to applying its proprietary TransCon drug-development technology platform to create innovative, long-acting therapeutic treatments for rare endocrine diseases and oncology.
Determining whether Ascendis Pharma stock represents an attractive purchase involves analyzing its proprietary TransCon technology platform, expanding commercial product portfolio, and strengthening bottom-line financial performance.